Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2010

01-03-2010 | Clinical Trial Report

The Next Era of HCV Antiviral Therapy Finally Begins: Part 1

Author: David Bobak

Published in: Current Infectious Disease Reports | Issue 2/2010

Login to get access

Excerpt

McHutchison JG, Everson GT, Gordon SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection [published correction appears in N Engl J Med 2009,361:1516]. N Engl J Med 2009, 360:1827–1838. …
Literature
1.
2.
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1–46.
3.
4.
Kronenberger B, Zeuzem S: Current and future treatment options for HCV . Ann Hepatol 2009, 8:103–112.PubMed
5.
Shimakami T, Lanford RE, Lemon SM: Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol 2009, 9:537–544.CrossRefPubMed
6.
Pereira AA, Jacobson IM: New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 2009, 6:403–411.CrossRefPubMed
7.
Gentile I, Carleo MA, Borgia F, et al.: The efficacy and safety of telaprevir—a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010, 19:151–159.CrossRefPubMed
8.
Weisberg IS, Jacobson IM: Telaprevir: hope on the horizon, getting closer. Clin Liver Dis 2009, 13:441–452.CrossRefPubMed
9.
McHutchison JG, Everson GT, Gordon SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection [published correction appears in N Engl J Med 2009, 361:1516]. N Engl J Med 2009, 360:1827–1838.CrossRefPubMed
10.
Hezode C, Forestier N, Dusheiko G, et al.: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839–1850.CrossRefPubMed
11.
Metadata
Title
The Next Era of HCV Antiviral Therapy Finally Begins: Part 1
Author
David Bobak
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 2/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0093-4

Other articles of this Issue 2/2010

Current Infectious Disease Reports 2/2010 Go to the issue

ReviewPaper

Topical Antibiotic Therapy of Chronic Rhinosinusitis

ReviewPaper

The Role of Adenovirus in Respiratory Tract Infections

ReviewPaper

Update on HHV-8-Associated Malignancies

ReviewPaper

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS): a Controversial Diagnosis

ReviewPaper

Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men

ReviewPaper

Recent Advances in the Understanding and Management of Kawasaki Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits